Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01201317 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 134
- Enrollment target
NCT01201317 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 134 participants.
The verdict
NCT01201317, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 134 participants
- Enrollment target
Study Summary
A study to investigate the analgesic efficacy of AZD2423 compared with placebo after 28 days treatment in patients with painful diabetic polyneuropathy.
Interventions
- DRUG Placebo
- DRUG AZD2423
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01201317
The ClinicalTrials.gov registry entry for NCT01201317 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01201317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01201317 about?
NCT01201317 is a clinical study titled "A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy". A study to investigate the analgesic efficacy of AZD2423 compared with placebo after 28 days treatment in patients with painful diabetic polyneuropathy.
What is the current status of trial NCT01201317?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 2010-09. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01201317?
The interventions under investigation include: Placebo (DRUG), AZD2423 (DRUG).
Who is sponsoring clinical trial NCT01201317?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.